GOLPH2 Protein Expression as a Biomarker for Prostate Cancer
Author Information
Author(s): Kristiansen G, Fritzsche F R, Wassermann K, Jäger C, Tölle A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H
Primary Institution: University Hospital Zurich
Hypothesis
This study aimed to analyze GOLPH2 protein expression in benign and malignant prostate lesions.
Conclusion
GOLPH2 is significantly upregulated in prostate cancer tissues and can serve as an additional marker for tissue-based diagnosis.
Supporting Evidence
- GOLPH2 protein was upregulated in 567 of 614 tumors (92.3%).
- AMACR was overexpressed in 583 of 614 tumors (95%).
- GOLPH2 expression was significantly higher in prostate cancer glands compared to normal glands.
Takeaway
GOLPH2 is a protein that can help doctors tell if someone has prostate cancer by looking at tissue samples.
Methodology
Immunohistochemical analysis of GOLPH2 protein expression was conducted on 614 radical prostatectomy specimens.
Potential Biases
Potential bias in the selection of tissue samples and the interpretation of immunohistochemical results.
Limitations
The study may not account for all cancer variants and benign mimickers, and GOLPH2's sensitivity is slightly lower than AMACR.
Participant Demographics
Participants were prostate cancer patients aged 43 to 74 years, with a median age of 62.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website